JournalsHub
.online
Find My Journal
FH

Frankie A. Holmes

Memorial Hermann Memorial City Medical Center US

ORCID 0000-0001-8364-3906
227
Publications
13,635
Citations
50
H-Index
108
i10-Index
0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. OA

F. Holmes, B. Moy, S. Delaloge, S. Chia, B. Ejlertsen - European Journal of Cancer, 2023
Cited by 26 Semantic Scholar

Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial

F. Holmes, D. Patt, Y. Manalo, Julie C. Smith, S. Papish - Cancer Research, 2022
Cited by 0 Semantic Scholar

Abstract P2-13-05: Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC)

N. Lin, D. Lueftner, A. Brufsky, S. Tolaney, M. Melisko - Cancer Research, 2022
Cited by 2 Semantic Scholar

45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial OA

A. Chan, B. Moy, J. Mansi, M. Gnant, C. Barrios - Unknown Venue, 2021
Cited by 0 Semantic Scholar

Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial OA

M. Martín, F. Holmes, B. Moy, J. Mansi, M. Gnant - Unknown Venue, 2021
Cited by 2 Semantic Scholar

Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial

F. Holmes, B. Moy, S. Delaloge, S. Chia, B. Ejlertsen - Poster Spotlight Session Abstracts, 2021
Cited by 4 Semantic Scholar

Abstract PS9-33: Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US

T. Brodtkorb, Cheryl McDade, D. Lalla, F. Holmes - Unknown Venue, 2021
Cited by 0 Semantic Scholar

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. OA

A. Chan, B. Moy, J. Mansi, B. Ejlertsen, F. Holmes - Clinical Breast Cancer, 2020
Cited by 188 Semantic Scholar

Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer OA

D. Collins, S. Madden, N. Gaynor, Dalal AlSultan, Marion Le Gal - Clinical Cancer Research, 2020
Cited by 52 Semantic Scholar

Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study OA

M. Mahoney, F. Holmes, Benjamin B. Cho - Unknown Venue, 2020
Cited by 1 Semantic Scholar

Research Topics

Cancer Treatment and Pharmacology (97) HER2/EGFR in Cancer Research (78) Breast Cancer Treatment Studies (59) Advanced Breast Cancer Therapies (47) Monoclonal and Polyclonal Antibodies Research (33)

Affiliations

University of Southern California
US 1996 - 1996
Rush University Medical Center
US 2005 - 2005
Memorial Hermann
US 2017 - 2017
McKesson (United States)
US 2019 - 2013
Amgen (United States)
US 2003 - 2003

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now